肝细胞肝癌的新辅助治疗

Neoadjuvant therapy for hepatocellular carcinoma

肝细胞肝癌是全球高发病率、高死亡率的恶性肿瘤。手术切除是其主要的根治性方法。然而术后高复发率,导致了较差的预后。新辅助治疗是指对于可切除的肝癌,在手术前进行抗肿瘤治疗,以达到降低肿瘤负荷、减少术后复发的作用。虽然越来越多的研究表明新辅助治疗能为肝癌患者带来生存益处。但是新辅助治疗的指征、适用人群、治疗方式、治疗周期、安全性等还存在争议。在此,本文就以上问题,以及新辅助治疗在肝细胞肝癌中的临床应用和研究进展作一综述。

Hepatocellular carcinoma(HCC)is a malignant tumor with high incidence rate and mortality in the world.Surgical resection is the main radical method.However,the high recurrence rate leads to poor prognosis.Neoadjuvant therapy refers to anti-tumor therapy for resectable HCC before surgery to reduce tumor load and postoperative recurrence.Although more and more studies show that neoadjuvant therapy can bring survival benefits to patients with liver cancer.However,the indication,applicable population,treatment mode,treatment cycle and safety of new adjuvant therapy are still controversial.In this review,we will review the above issues,as well as the clinical application and research progress of neoadjuvant in hepatocellular carcinoma.